Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:31 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Efficacy & Safety of Nintedanib in Patients With Progressive Fibrosing Coal Mine Dust-Induced Interstitial Lung Disease
NCT05067517 · West Virginia University · PHASE3 · withdrawn · last registry update 2025-02-24 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Unable to enroll any subjects. IRB closed study in agreement with PI.” | – | Registry record, West Virginia University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PDGFRB within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-02-23Phase 3 first posted: European Organisation for Research and Treatment of Cancer - EORTC, Gilteritinib + Venetoclax (NCT07425808)
- 2026-02-06Phase 3 first posted: Nanjing Sanhome Pharmaceutical, Co., Ltd., SH006 + Bevacizumab (NCT07392866)
- 2026-02-03Phase 3 first posted: Shanghai JMT-Bio Inc., JSKN003 + Physician choiced treatment, include: TAS-102, Regorafenib, Fruquintinib. (NCT07384377)
- 2026-01-30Phase 3 first posted: Ningbo Newbay Technology Development Co., Ltd, NB003 + regorafenib (NCT07379047)
- 2026-01-29Results posted on the registry: Indiana University, Imatinib Mesylate (NCT03997903)
- 2026-01-29Also stopped (terminated): Indiana University, Imatinib Mesylate (NCT03997903)
- 2026-01-20Results posted on the registry: Bristol-Myers Squibb, BMS-986288 + Nivolumab (NCT03994601)
- 2026-01-20Also stopped (terminated): Anwaar Saeed, Regorafenib + Pembrolizumab (NCT06006923)
- 2026-01-13Phase 3 first posted: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, BMS-986353 + Fludarabine (NCT07335562)
- 2026-01-13Also stopped (terminated): Novartis Pharmaceuticals, LTP001 + Placebo (NCT05497284)
- 2025-12-24Results posted on the registry: Bristol-Myers Squibb, Nivolumab + Sorafenib (NCT01658878)
- 2025-12-23Phase 3 first posted: Argyrios Tzouvelekis, Intravenous immunoglobulin (IVIG) + Usual treatment (NCT07299695)
- 2025-12-23Phase 3 first posted: Xi'an Xintong Pharmaceutical Research Co.,Ltd., Pracytarabine + regorafenib (NCT07300488)
- 2025-12-18Results posted on the registry: SWOG Cancer Research Network, Bosutinib + Dasatinib (NCT03654768)
- 2025-12-11Results posted on the registry: Exelixis, Cabozantinib + Cabozantinib (NCT03755791)
- 2025-12-04Phase 3 first posted: Nanfang Hospital, Southern Medical University, Sorafenib (SORA) + Venetoclax (VEN) (NCT07264010)
- 2025-12-03Results posted on the registry: Bristol-Myers Squibb, Nivolumab + Trametinib (NCT03377361)
- 2025-12-02Results posted on the registry: Boehringer Ingelheim, BI 1015550 + Nintedanib (NCT06070610)
- 2025-11-10Results posted on the registry: Boehringer Ingelheim, BI 836880 + Ezabenlimab (NCT03468426)
- 2025-11-05Results posted on the registry: University of Nebraska, Cytarabine + Decitabine (NCT03226418)
- 2025-10-27Results posted on the registry: AstraZeneca, Durvalumab + Danvatirsen (NCT03334617)
- 2025-10-23Also stopped (suspended): Mirror Biologics, Inc., AlloStim® immunotherapy + FOLFOX regimen (NCT05033522)
- 2025-10-21Phase 3 first posted: GlaxoSmithKline, IDRX-42 + Sunitinib (NCT07218926)
- 2025-10-14Results posted on the registry: BeiGene, Tislelizumab + Sorafenib (NCT03412773)
- 2025-10-02Phase 3 first posted: Nanfang Hospital, Southern Medical University, targeted drug (NCT07203352)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision